Will DigitalOcean Stock Bounce Back?
DigitalOcean (NYSE:DOCN) has run into the proverbial brick wall with…
Sell
50
AYTU Quote, Financials, Valuation and Earnings
Last price:
$1.97
Seasonality move
:
-32.95%
Day range:
$1.90 - $2.06
52-week range:
$0.95 - $3.24
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.19x
P/B ratio:
0.35x
Volume:
223.3K
Avg. volume:
2.5M
1-year change:
-38.36%
Market cap:
$12.1M
Revenue:
$81M
EPS (TTM):
-$1.02
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Aytu BioPharma has 308.16% upside to fair value with a price target of $8.00 per share.
AYTU vs. S&P 500
-
Over the past 5 trading days, Aytu BioPharma has underperformed the S&P 500 by -5.51% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Aytu BioPharma does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Aytu BioPharma has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Aytu BioPharma reported revenues of $18.5M.
Earnings Growth
-
Aytu BioPharma has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Aytu BioPharma reported earnings per share of $0.21.
Enterprise value:
15.3M
EV / Invested capital:
0.27x
Price / LTM sales:
0.19x
EV / EBIT:
4.48x
EV / Revenue:
0.19x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.67x
Price / Operating cash flow:
28.82x
Enterprise value / EBITDA:
1.45x
Gross Profit (TTM):
$52.2M
Return On Assets:
1.36%
Net Income Margin (TTM):
2.01%
Return On Equity:
5.32%
Return On Invested Capital:
3.42%
Operating Margin:
13.12%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $104.1M | $81.3M | $81.7M | $14M | $18.5M | |
| Gross Profit | $62.9M | $56.6M | $52.2M | $10.4M | $12.8M | |
| Operating Income | -$22.2M | $3.7M | -$1.9M | -$1.4M | $2.4M | |
| EBITDA | -$13.3M | $6.3M | $10.6M | $1M | $6.2M | |
| Diluted EPS | -$14.16 | -$2.63 | -$1.02 | -$0.52 | $0.21 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $100M | $77.9M | $78.5M | $71.1M | $72.5M | |
| Total Assets | $271.6M | $168.8M | $147.2M | $128.9M | $124.2M | |
| Current Liabilities | $83.7M | $80.4M | $85.4M | $83.7M | $70.7M | |
| Total Liabilities | $128.4M | $107.7M | $106.3M | $98.1M | $89.3M | |
| Total Equity | $143.1M | $61.1M | $40.9M | $30.8M | $34.9M | |
| Total Debt | $23.1M | $17.7M | $25.1M | $16.7M | $21.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$21.6M | $8.8M | -$5.5M | -$254K | -$6.5M | |
| Cash From Investing | -$3K | -$450K | $423K | -$45K | -$69K | |
| Cash From Financing | $13.2M | -$7.7M | $3.5M | $530K | $4.3M | |
| Free Cash Flow | -$21.6M | $8.8M | -$5.7M | -$254K | -$6.5M | |
AYTU
Sector
Market Cap
$12.1M
$34.8M
Price % of 52-Week High
60.49%
44.2%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-38.37%
-41.1%
Beta (5-Year)
-0.105
0.659
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.01
200-day SMA
Buy
Level
$1.74
Bollinger Bands (100)
Buy
Level
1.1 - 1.72
Chaikin Money Flow
Sell
Level
-76.7M
20-day SMA
Buy
Level
$1.55
Relative Strength Index (RSI14)
Buy
Level
63.29
ADX Line
Buy
Level
48.44
Williams %R
Neutral
Level
-49.3333
50-day SMA
Buy
Level
$1.29
MACD (12, 26)
Buy
Level
0.24
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Neutral
Level
279.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.2544)
Sell
CA Score
(Annual)
Level (-1.6302)
Buy
Beneish M-Score
(Annual)
Level (-3.2396)
Buy
Momentum Score
Level (2)
Sell
Ohlson Score
Level (3.6692)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
Stock Forecast FAQ
In the current month, AYTU has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AYTU average analyst price target in the past 3 months is $8.00.
-
Where Will Aytu BioPharma Stock Be In 1 Year?
According to analysts, the consensus estimate is that Aytu BioPharma share price will rise to $8.00 per share over the next 12 months.
-
What Do Analysts Say About Aytu BioPharma?
Analysts are divided on their view about Aytu BioPharma share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Aytu BioPharma is a Sell and believe this share price will drop from its current level to $8.00.
-
What Is Aytu BioPharma's Price Target?
The price target for Aytu BioPharma over the next 1-year time period is forecast to be $8.00 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AYTU A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Aytu BioPharma is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of AYTU?
You can purchase shares of Aytu BioPharma via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Aytu BioPharma shares.
-
What Is The Aytu BioPharma Share Price Today?
Aytu BioPharma was last trading at $1.97 per share. This represents the most recent stock quote for Aytu BioPharma. Yesterday, Aytu BioPharma closed at $1.96 per share.
-
How To Buy Aytu BioPharma Stock Online?
In order to purchase Aytu BioPharma stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Cognizant Stock Be In 5 Years?
Cognizant Technologies (NASDAQ:CTSH) is a global provider of IT services…
NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA (NASDAQ:NVDA) and Broadcom (NASDAQ:AVGO) are two of the hottest…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 38x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 45x
Sell
33
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Buy
60
MRUS alert for May 24
Merus NV [MRUS] is up 32.55% over the past day.
Buy
57
RGC alert for May 24
Regencell Bioscience Holdings [RGC] is up 28.43% over the past day.
Buy
90
OKLO alert for May 24
Oklo [OKLO] is up 23.11% over the past day.
